On the afternoon of January 28, Mr. Ong Ye Kung, Minister for Health Coordinating Minister for of Social Policies of Singapore, together with Mr. Peter Tan, Ambassador of the Republic of Singapore to China, Ministry of Foreign Affair, led a delegation to visit MindRank at its headquarters in Hangzhou for an inspection and exchange.

The delegation was received by Dr. Zhangming Niu, Founder and CE of MindRank, along with members of the company’s core management and R&D team.

During the visit, the delegation of MOH Singapore toured MindRank’s Hangzhou R&D facilities and participated in in-depth discussions with the MindRank team. At the meeting, Dr. Niu introduced their AI drug discovery platform, and the latest research progress.

Starting from unmet upstream needs in drug discovery, MindRank utilizes its proprietary platforms Molecule Pro™ to accelerate the development of innovative small molecule drugs. The platform can significantly increase the success rate of R&D and reduce development costs. Among its key pipeline assets, MDR-001, an Oral GLP-1RA Small Molecule Engineered with AI, has advanced into Phase III clinical trials. The company has also established deep collaborations with MNCs.

During the visit, Minister Ong and the delegation gained detailed insights into MindRank’s AI-driven drug discovery approach. Both sides exchanged views on the underlying technologies of AI-driven drug discovery platforms, the progress of candidate drugs, data management, and regulatory considerations.